A novel and potent brain penetrant inhibitor of extracellular vesicle release

Camilo Rojas, Michal Sala, Ajit G. Thomas, Amrita Datta Chaudhuri, Seung Wan Yoo, Zhigang Li, Ranjeet P. Dash, Rana Rais, Norman Haughey, Radim Nencka, Barbara Slusher

Research output: Contribution to journalArticle

Abstract

Background and Purpose: Extracellular vesicles (EVs) are constitutively shed from cells and released by various stimuli. Their protein and RNA cargo are modified by the stimulus, and in disease conditions can carry pathological cargo involved in disease progression. Neutral sphingomyelinase 2 (nSMase2) is a major regulator in at least one of several independent routes of EV biogenesis, and its inhibition is a promising new therapeutic approach for neurological disorders. Unfortunately, known inhibitors exhibit μM potency, poor physicochemical properties, and/or limited brain penetration. Here, we sought to identify a drug-like inhibitor of nSMase2. Experimental Approach: We conducted a human nSMase2 high throughput screen (>365,000 compounds). Selected hits were optimized focusing on potency, selectivity, metabolic stability, pharmacokinetics, and ability to inhibit EV release in vitro and in vivo. Key Results: We identified phenyl(R)-(1-(3-(3,4-dimethoxyphenyl)-2,6-dimethylimidazo[1,2-b]pyridazin-8-yl)pyrrolidin-3-yl)-carbamate (PDDC), a potent (pIC50 = 6.57) and selective non-competitive inhibitor of nSMase2. PDDC was metabolically stable, with excellent oral bioavailability (%F = 88) and brain penetration (AUCbrain/AUCplasma = 0.60). PDDC dose-dependently (pEC50 = 5.5) inhibited release of astrocyte-derived extracellular vesicles (ADEV). In an in vivo inflammatory brain injury model, PDDC robustly inhibited ADEV release and the associated peripheral immunological response. A closely related inactive PDDC analogue was ineffective. Conclusion and Implications: PDDC is a structurally novel, potent, orally available, and brain penetrant inhibitor of nSMase2. PDDC inhibited release of ADEVs in tissue culture and in vivo. PDDC is actively being tested in animal models of neurological disease and, along with closely related analogues, is being considered for clinical translation.

Original languageEnglish (US)
JournalBritish Journal of Pharmacology
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Sphingomyelin Phosphodiesterase
Brain
Astrocytes
Animal Disease Models
Carbamates
Extracellular Vesicles
pyrenedodecanoylcarnitine
Nervous System Diseases
Brain Injuries
Biological Availability
Disease Progression
Pharmacokinetics
RNA
Pharmaceutical Preparations
Proteins

ASJC Scopus subject areas

  • Pharmacology

Cite this

A novel and potent brain penetrant inhibitor of extracellular vesicle release. / Rojas, Camilo; Sala, Michal; Thomas, Ajit G.; Datta Chaudhuri, Amrita; Yoo, Seung Wan; Li, Zhigang; Dash, Ranjeet P.; Rais, Rana; Haughey, Norman; Nencka, Radim; Slusher, Barbara.

In: British Journal of Pharmacology, 01.01.2019.

Research output: Contribution to journalArticle

@article{41d7c6e1f9d24e879f0a32130901cf03,
title = "A novel and potent brain penetrant inhibitor of extracellular vesicle release",
abstract = "Background and Purpose: Extracellular vesicles (EVs) are constitutively shed from cells and released by various stimuli. Their protein and RNA cargo are modified by the stimulus, and in disease conditions can carry pathological cargo involved in disease progression. Neutral sphingomyelinase 2 (nSMase2) is a major regulator in at least one of several independent routes of EV biogenesis, and its inhibition is a promising new therapeutic approach for neurological disorders. Unfortunately, known inhibitors exhibit μM potency, poor physicochemical properties, and/or limited brain penetration. Here, we sought to identify a drug-like inhibitor of nSMase2. Experimental Approach: We conducted a human nSMase2 high throughput screen (>365,000 compounds). Selected hits were optimized focusing on potency, selectivity, metabolic stability, pharmacokinetics, and ability to inhibit EV release in vitro and in vivo. Key Results: We identified phenyl(R)-(1-(3-(3,4-dimethoxyphenyl)-2,6-dimethylimidazo[1,2-b]pyridazin-8-yl)pyrrolidin-3-yl)-carbamate (PDDC), a potent (pIC50 = 6.57) and selective non-competitive inhibitor of nSMase2. PDDC was metabolically stable, with excellent oral bioavailability ({\%}F = 88) and brain penetration (AUCbrain/AUCplasma = 0.60). PDDC dose-dependently (pEC50 = 5.5) inhibited release of astrocyte-derived extracellular vesicles (ADEV). In an in vivo inflammatory brain injury model, PDDC robustly inhibited ADEV release and the associated peripheral immunological response. A closely related inactive PDDC analogue was ineffective. Conclusion and Implications: PDDC is a structurally novel, potent, orally available, and brain penetrant inhibitor of nSMase2. PDDC inhibited release of ADEVs in tissue culture and in vivo. PDDC is actively being tested in animal models of neurological disease and, along with closely related analogues, is being considered for clinical translation.",
author = "Camilo Rojas and Michal Sala and Thomas, {Ajit G.} and {Datta Chaudhuri}, Amrita and Yoo, {Seung Wan} and Zhigang Li and Dash, {Ranjeet P.} and Rana Rais and Norman Haughey and Radim Nencka and Barbara Slusher",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/bph.14789",
language = "English (US)",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - A novel and potent brain penetrant inhibitor of extracellular vesicle release

AU - Rojas, Camilo

AU - Sala, Michal

AU - Thomas, Ajit G.

AU - Datta Chaudhuri, Amrita

AU - Yoo, Seung Wan

AU - Li, Zhigang

AU - Dash, Ranjeet P.

AU - Rais, Rana

AU - Haughey, Norman

AU - Nencka, Radim

AU - Slusher, Barbara

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background and Purpose: Extracellular vesicles (EVs) are constitutively shed from cells and released by various stimuli. Their protein and RNA cargo are modified by the stimulus, and in disease conditions can carry pathological cargo involved in disease progression. Neutral sphingomyelinase 2 (nSMase2) is a major regulator in at least one of several independent routes of EV biogenesis, and its inhibition is a promising new therapeutic approach for neurological disorders. Unfortunately, known inhibitors exhibit μM potency, poor physicochemical properties, and/or limited brain penetration. Here, we sought to identify a drug-like inhibitor of nSMase2. Experimental Approach: We conducted a human nSMase2 high throughput screen (>365,000 compounds). Selected hits were optimized focusing on potency, selectivity, metabolic stability, pharmacokinetics, and ability to inhibit EV release in vitro and in vivo. Key Results: We identified phenyl(R)-(1-(3-(3,4-dimethoxyphenyl)-2,6-dimethylimidazo[1,2-b]pyridazin-8-yl)pyrrolidin-3-yl)-carbamate (PDDC), a potent (pIC50 = 6.57) and selective non-competitive inhibitor of nSMase2. PDDC was metabolically stable, with excellent oral bioavailability (%F = 88) and brain penetration (AUCbrain/AUCplasma = 0.60). PDDC dose-dependently (pEC50 = 5.5) inhibited release of astrocyte-derived extracellular vesicles (ADEV). In an in vivo inflammatory brain injury model, PDDC robustly inhibited ADEV release and the associated peripheral immunological response. A closely related inactive PDDC analogue was ineffective. Conclusion and Implications: PDDC is a structurally novel, potent, orally available, and brain penetrant inhibitor of nSMase2. PDDC inhibited release of ADEVs in tissue culture and in vivo. PDDC is actively being tested in animal models of neurological disease and, along with closely related analogues, is being considered for clinical translation.

AB - Background and Purpose: Extracellular vesicles (EVs) are constitutively shed from cells and released by various stimuli. Their protein and RNA cargo are modified by the stimulus, and in disease conditions can carry pathological cargo involved in disease progression. Neutral sphingomyelinase 2 (nSMase2) is a major regulator in at least one of several independent routes of EV biogenesis, and its inhibition is a promising new therapeutic approach for neurological disorders. Unfortunately, known inhibitors exhibit μM potency, poor physicochemical properties, and/or limited brain penetration. Here, we sought to identify a drug-like inhibitor of nSMase2. Experimental Approach: We conducted a human nSMase2 high throughput screen (>365,000 compounds). Selected hits were optimized focusing on potency, selectivity, metabolic stability, pharmacokinetics, and ability to inhibit EV release in vitro and in vivo. Key Results: We identified phenyl(R)-(1-(3-(3,4-dimethoxyphenyl)-2,6-dimethylimidazo[1,2-b]pyridazin-8-yl)pyrrolidin-3-yl)-carbamate (PDDC), a potent (pIC50 = 6.57) and selective non-competitive inhibitor of nSMase2. PDDC was metabolically stable, with excellent oral bioavailability (%F = 88) and brain penetration (AUCbrain/AUCplasma = 0.60). PDDC dose-dependently (pEC50 = 5.5) inhibited release of astrocyte-derived extracellular vesicles (ADEV). In an in vivo inflammatory brain injury model, PDDC robustly inhibited ADEV release and the associated peripheral immunological response. A closely related inactive PDDC analogue was ineffective. Conclusion and Implications: PDDC is a structurally novel, potent, orally available, and brain penetrant inhibitor of nSMase2. PDDC inhibited release of ADEVs in tissue culture and in vivo. PDDC is actively being tested in animal models of neurological disease and, along with closely related analogues, is being considered for clinical translation.

UR - http://www.scopus.com/inward/record.url?scp=85071747936&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071747936&partnerID=8YFLogxK

U2 - 10.1111/bph.14789

DO - 10.1111/bph.14789

M3 - Article

C2 - 31273753

AN - SCOPUS:85071747936

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

ER -